Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective

MoS2/LaF3 for enhanced photothermal therapy performance of poorly-differentiated hepatoma

Photothermal therapy (PTT) based on nanoparticle had been widely used to antitumor treatment. However, low photothermal conversion efficiency (PCE) is the main hurdle for antitumor treatment. To improve the PCE and gain ideal clinical the nanoparticle with higher photothermal conversion efficiency, we have developed a highly efficient solar absorber with MoS₂/LaF₃/ polydimethylsiloxane(PDMS) which can enhance the absorption of solar irradiation engergy, however, its photothermal effect irradiated by near-infrared light has not yet been investigated. The knowledge absence in photothermal effect will impede MoS₂/LaF₃/PDMS to be used for cancer therapy in clinic. In this study, we applied LaF₃-loaded, MoS₂-based photothermal conversion agents (PTAs) for improved photothermal cancer therapy. The study showed that the MoS₂/LaF₃ nanoflowers showed higher photothermal conversion efficiency (PCE, 42.5%) and could more effectively inhibit cancer cell proliferation compared to MoS₂-based PTT agents in vitro. In vivo, the results further revealed that photothermal therapy using MoS₂/LaF₃ nanoflowers could significantly inhibit solid tumor growth. The study clearly demonstrated that MoS₂/LaF₃ could work at under low power NIR Laser in vitro and in vivo, resulting in a very impressive therapeutic effect in tumor-bearing mice. The MoS₂/LaF₃ nanoflowers will be prominent candidate nanoparticle for effective inhibiting tumor growth by photothermal therapy.

In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis

This chapter deconstructs the process of angiogenesis into its component parts in order to provide simple assays to measure discrete endothelial cell functions. The techniques described will be suitable for studying stimulators and/or inhibitors of angiogenesis and determining which aspect of the process is modulated. The assays are designed to be robust and straightforward, using human umbilical vein endothelial cells, but with an option to use other sources such as microvascular endothelial cells from various tissues or lymphatic endothelial cells. It must be appreciated that such reductionist approaches cannot cover the complexity of the angiogenic process as a whole, incorporating as it does a myriad of positive and negative signals, three-dimensional interactions with host tissues and many accessory cells including fibroblasts, macrophages, pericytes and platelets. The extent to which in vitro assays predict physiological or pathological processes in vivo (e.g., wound healing, tumor angiogenesis) or surrogate techniques such as the use of Matrigel™ plugs, sponge implants, corneal assays etc remains to be determined.